Table 2.
Proportion of polymorphisms according to time in therapeutic range.
| Total cohort (n=212) | TTR <70% (n=128, 60.4%) | TTR ≥70% (n=84, 39.6%) | p-value | |
|---|---|---|---|---|
| VKORC ≥ 1 allele T, (TT/CT), n (%) | 138 (65.1) | 85 (66.4) | 53 (63.1) | 0.621 |
| CYP2C9 ∗ 2 ≥1 allele T (TT/CT), n (%) | 75 (35.4) | 44 (34.4) | 31 (36.9) | 0.706 |
| CYP2C9 ∗ 3 ≥ 1 allele C (CC/CA), n (%) | 35 (16.5) | 20 (15.6) | 15 (17.9) | 0.669 |
| MIR133A2 ≥ 1 allele A (AA/GG), n (%) | 82 (38.7) | 51 (39.8) | 31 (36.9) | 0.667 |
TTR, time in therapeutic range.